#	Pagina
attuale pagina	/open-h2020/projects/196290/results.html

Report

Teaser, summary, work performed and final results

Periodic Reporting for period 1 - Multidyn (Patented advanced low-cost multiwell cell-culture system for in-vitro physiologically relevant biomarker screening)

Teaser

Summary

The goal of the project is to develop a multipurpose innovative platform for the biomarker discovery. It will be composed by:
a. an advanced fluidic chamber, standardize on the dimensions of a multiwell plate, and allowing for the implementation of in-vitro models highly correlated with the reality
b. removable and disposable scaffolds for 3D in-vitro models structure
c. high content imaging module for screening of the fluidic chamber, real time monitoring, avoiding the need of distructive chemical reagents commonly used in optical studies.
This platform will be used for the validation of a diabetes in-vitro model and the analysis of biomarkers related with this kind of pathology. The partners of the project will be supported by subcontracts for the large scale production line implementation and the validation of the system with biological tools. The long term goal is to have the possibility to use this platform to open new markets for the partners, increasing the network of potential clients in the pharmaceutical field.

Work performed

During PH1 meetings between partners have been organized in order to define the specifications of the platform. Starting from the existing technology, each partner highlighted how to implement new features and integrate each module with the others, in order to obtain a final and innovative product. Moreover it was decided the business model to promote the system and reach the potential clients during the project. The production lines of each module have been designed in order to be ready for the large scale production and the penetration of the EU market at the end of the project. IVTech decided to have in-house production lines for both scaffolds and pumps as well as Cetlltool decided to have in-house production of Dynram. MultiDyn production line will be outsourced and in particular OMP Microprecision will be the manufacturer who is going to design and realize the moulds, and produce the MultiDyn system by injection moulding.

Final results

The expected results are related to scientific and business results. The first ones are linked with a significant improvement in the discovery of biomarkers, using our innovative technology. The validation of the in-vitro diabetes model will permit the discovery of new molecules correlated with the early stage of the pathology, allowing for the development of new and more efficient drugs. It will allow for an in-depth understanding of the early stage pathology mechanism, reducing the risk for patients with more predictive and correlated in-vitro models of the human reality. The business expected results are related with the possibility to penetrate a the EU market of biomarker discovery, characterized by several big potential customers and then highly attractive of new investments. Both the partners will have the possibility to structure the companies for the large scale production, obtaining new facilities and know-how for the implementation of new technology which will probably become the core business of each company.